1. Home
  2. NRDS vs ANNX Comparison

NRDS vs ANNX Comparison

Compare NRDS & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NerdWallet Inc.

NRDS

NerdWallet Inc.

N/A

Current Price

$7.98

Market Cap

640.8M

Sector

Technology

ML Signal

N/A

Logo Annexon Inc.

ANNX

Annexon Inc.

N/A

Current Price

$4.23

Market Cap

726.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NRDS
ANNX
Founded
2009
2011
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
640.8M
726.1M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
NRDS
ANNX
Price
$7.98
$4.23
Analyst Decision
Buy
Buy
Analyst Count
5
10
Target Price
$11.50
★ $17.00
AVG Volume (30 Days)
743.4K
★ 3.6M
Earning Date
11-05-2026
11-17-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 68.42
N/A
EPS
★ 0.59
N/A
Revenue
★ $836,600,000.00
N/A
Revenue This Year
$9.10
N/A
Revenue Next Year
$6.02
N/A
P/E Ratio
$20.02
★ N/A
Revenue Growth
★ 21.67
N/A
52 Week Low
$7.33
$2.54
52 Week High
$16.24
$7.18

Technical Indicators

Market Signals
Indicator
NRDS
ANNX
Relative Strength Index (RSI) 32.99 55.08
Support Level $7.84 $3.71
Resistance Level $10.16 $4.37
Average True Range (ATR) 0.52 0.26
MACD -0.17 0.06
Stochastic Oscillator 5.28 66.48

Price Performance

Historical Comparison
NRDS
ANNX

About NRDS NerdWallet Inc.

Nerdwallet Inc is a company that provides consumer-driven advice about personal finance through its platform by connecting individuals and small and mid-sized businesses (SMBs) with providers of financial products. The Company's platform comprises three primary components: Editorial and Content Publishing, Marketplace and Referral Services, and Financial Services. It operates in the United States, Canada, and the United Kingdom.

About ANNX Annexon Inc.

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.

Share on Social Networks: